diabetic retinopathy glp 1 Are GLP-1 receptor agonists and foes or friends? GLP-1 receptor agonists and the

To view or add a comment, sign in EU Approval Is Sought for Teclistamab Monotherapy in R/R Myeloma After 1 Line of Therapy Key Takeaways MajesTEC9 met PFS benefit with HR 0.29 versus SOC PVd or Kd, and showed OS HR 0.60

Discontinuation of GLP-1 medications typically results in predictable physiological changes as the pharmacological effects wear off

While all of these potential benefits are exciting, experts said they need much more study, and even then, whether they might ever be utilized as a treatment for schizophrenia, for example, would depend on a number of factors: how much and how consistently they work, as well as how they compare to treatments that are already available

Di Prospero NA, Yee J, Frustaci ME, Samtani MN, Alba M, Fleck P